Latest news

View all

Pharma Business – July 7, 2025

AstraZeneca’s Imfinzi approved in the EU

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).

Biotech Award – July 2, 2025

Lars Lannfelt to receive the Hartwig Piepenbrock-DZNE Prize

BioArctic’s founder, Professor Lars Lannfelt, will receive the prize for his pioneering contributions to the understanding of Alzheimer’s disease and to the development of the drug lecanemab.

Agreement – July 2, 2025

Alvotech and Advanz Pharma enter agreement 

The companies have entered into a supply and commercialization agreement for AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).

New Market – July 2, 2025

Camurus’ Oczyesa receives marketing authorization in the EU

Camurus has announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.

Biotech Business – July 2, 2025

Pixelgen awarded USD 14.7 million in blended funding 

The company has been awarded grant and equity financing from the European Innovation Council (EIC) Accelerator, a funding initiative under the European Union’s Horizon Europe program designed to support highly innovative start-ups with disruptive technologies.

Science Award – June 29, 2025

He is the winner of the 2025 Lennart Nilsson Award

Doctor Maximilian Ackermann, currently working as a Professor of Pathology at the RWTH University Clinics Aachen and Helios University Hospital Wuppertal, Germany, and as anatomist at the Johannes Gutenberg University Mainz is awarded the 2025 Lennart Nilsson Award for his outstanding contributions to scientific imaging, revealing critical insights into diseases, such as COVID-19 and cancer.

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • The Changing World: We take a closer look at the new US administration and its consequences on R&D and public health, China’s journey to become the world’s new life science powerhouse, Europe’s efforts to strengthen its life science competitiveness, and Nordic collaboration in stockpiling medicines.
  • Investment Outlook: Nordic and US investors and VCs share their best tips for finding financing and they predict the life science investment landscape 2025 and beyond.
  • Hot topics: Learn more about how findings in aging research and geroscience enable us to age healthier and how our vast data resources can be used to create actionable insights that lead to real-world impact.
  • Careers: A Head of Marketing explains what it means to lead marketing in a biotechnology company and the challenges that come with the job.
Subscribe now

Opinion & debate

Clinical Trials

Clinical Trials – June 19, 2025

BioArctic to initiate next cohorts in Phase 2a study

The interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated.

Clinical Trials – June 18, 2025

Kancera reports positive top-line results

The company has announced results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer.

Clinical Trials – June 18, 2025

Abera announces new study results

The company has presented results from a recently completed study that further demonstrates the potential of its vaccine platform for pandemic preparedness.

Clinical Trials – June 10, 2025

LEO Pharma initiates Phase 2a trial

The phase 2a proof-of-concept DELTA NEXT trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP).

Clinical Trials – June 4, 2025

OncoZenge appoints LINK Medical to execute Phase 3 feasibility study

LINK Medical has been engaged to conduct a feasibility study in Europe for the company’s planned Phase 3 study for European approval of BupiZenge.

Clinical Trials – May 26, 2025

Active lymphoma eliminated in two out of three patients in the first cohort of Elicera’s CARMA study

Preliminary principal investigator-assessed outcomes from the first patient cohort in the ongoing Phase I/IIa CARMA study with ELC-301 show that two out of three treated patients had no active lymphoma detected on specialized scans, achieving a complete metabolic response.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Nobel Prize Discoveries – March 28, 2021

CRISPR/Cas9 – Rewriting the code of life

The discovery of CRISPR/Cas9 genetic scissors has revolutionized a lot of research areas, not least within life sciences, and the technology is bringing hope for new cancer therapies and the treatment of inherited diseases. The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna’s discovery of CRISPR/Cas9 genetic scissors. This enzyme […]

Science article – April 25, 2025

World Malaria Day 2025: The ongoing challenge of putting an end to malaria

In 2023, there were an estimated 263 million malaria cases, and 597,000 malaria deaths, making it a prioritized field for many researchers around the world. In Umeå, Sweden, Professor Oliver Billker’s group is focusing on the basic biology of the parasite, with the goal to develop new drugs and vaccines and understand why some mosquito species transmit malaria while others do not.

Profiles in Science – June 24, 2024

Exclusive interview: Jens Juul Holst

His is not a household name, but the drugs developed thanks to Danish scientist Jens Juul Holst’s research certainly are.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.